Literature DB >> 32820113

Immunotherapy with a sting.

Thomas F Gajewski1, Emily F Higgs2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32820113     DOI： 10.1126/science.abc6622

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  11 in total

1.  Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.

Authors:  Lisa Haas; Anais Elewaut; Camille L Gerard; Christian Umkehrer; Lukas Leiendecker; Malin Pedersen; Izabela Krecioch; David Hoffmann; Maria Novatchkova; Mario Kuttke; Tobias Neumann; Ines Pires da Silva; Harriet Witthock; Michel A Cuendet; Sebastian Carotta; Kevin J Harrington; Johannes Zuber; Richard A Scolyer; Georgina V Long; James S Wilmott; Olivier Michielin; Sakari Vanharanta; Thomas Wiesner; Anna C Obenauf
Journal:  Nat Cancer       Date:  2021-07-15

Review 2.  Advances in plant-derived natural products for antitumor immunotherapy.

Authors:  Yi Yang; Qinying Liu; Xianai Shi; Qiuhong Zheng; Li Chen; Yang Sun
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

Review 3.  Novel classes of immunotherapy for breast cancer.

Authors:  Alberto Hernando-Calvo; David W Cescon; Philippe L Bedard
Journal:  Breast Cancer Res Treat       Date:  2021-10-08       Impact factor: 4.872

Review 4.  Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce A "Hot" Tumor Microenvironment That Is Responsive to Immunotherapy.

Authors:  Robin Reschke; Daniel J Olson
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

5.  Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.

Authors:  Maite Alvarez; Carmen Molina; Carlos E De Andrea; Myriam Fernandez-Sendin; Maria Villalba; Jose Gonzalez-Gomariz; Maria Carmen Ochoa; Alvaro Teijeira; Javier Glez-Vaz; Fernando Aranda; Miguel F Sanmamed; Maria E Rodriguez-Ruiz; Xinyi Fan; Wen H Shen; Pedro Berraondo; Marisol Quintero; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

6.  Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.

Authors:  Xiaoqi Sun; Yu Zhang; Jiaqian Li; Kyung Soo Park; Kai Han; Xingwu Zhou; Yao Xu; Jutaek Nam; Jin Xu; Xiaoyue Shi; Lei Wei; Yu Leo Lei; James J Moon
Journal:  Nat Nanotechnol       Date:  2021-09-30       Impact factor: 40.523

Review 7.  Therapeutic strategies to remodel immunologically cold tumors.

Authors:  Minyu Wang; Sen Wang; Jayesh Desai; Joseph A Trapani; Paul J Neeson
Journal:  Clin Transl Immunology       Date:  2020-12-08

8.  Non-canonical roles of apoptotic and DNA double-strand break repair factors in mediating cellular response to ionizing radiation.

Authors:  Chuan-Yuan Li
Journal:  Int J Radiat Biol       Date:  2021-07-14       Impact factor: 2.694

Review 9.  Targeting the spectrum of immune checkpoints in prostate cancer.

Authors:  Laura A Sena; Samuel R Denmeade; Emmanuel S Antonarakis
Journal:  Expert Rev Clin Pharmacol       Date:  2021-07-15       Impact factor: 4.108

10.  STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS).

Authors:  Yasmine Messaoud-Nacer; Elodie Culerier; Stéphanie Rose; Isabelle Maillet; Nathalie Rouxel; Sylvain Briault; Bernhard Ryffel; Valerie F J Quesniaux; Dieudonnée Togbe
Journal:  Cell Death Dis       Date:  2022-03-25       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.